FDA approves new nonhormonal medication for menopause hot flashes

Betsy Goodfellow | May 15, 2023 | News story | Medical Communications FDA, HRT, Veozah, hot flashes, menopause 

The US Food and Drug Administration (FDA) has announced its approval of Veozah (fezolinetant), an oral medication to treat moderate to severe vasomotor symptoms, or hot flashes, caused by menopause.

The drug is the first neurokinin 3 (NK3) receptor antagonist approved by the FDA to treat these symptoms, and works by binding to and blocking the activities of the NK3 receptor, which plays a role in the brain’s regulation of body temperature.

According to the FDA’s press release, “hot flashes occur in around 80% of menopausal women and can include periods of sweating, flushing and chills lasting for several minutes,” so new treatment options are likely to be gratefully received.

The efficacy of the drug was assessed in the 12-week, randomised, placebo-controlled, double-blind portions of two phase 3 clinical trials. The most common side effects of the drug included abdominal pain, diarrhea, insomnia, back pain, hot flashes and elevated hepatic transaminases.

Janet Maynard, MD MHS, director of the Office of Rare Diseases, Paediatrics, Urologic and Reproductive Medicine within the FDA’s Center for Drug Evaluation and Research, commented: “Hot flashes as a result of menopause can be a serious physical burden on women and impact their quality of life. The introduction of a new molecule to treat moderate to severe menopausal hot flashes will provide an additional safe and effective treatment option for women.”

Betsy Goodfellow

Related Content

FDA approves first oral antiviral to treat adult patients with COVID-19

The US Food and Drug Administration (FDA) has announced that it has approved the oral …

ZOLL remedē System receives FDA approval for sleep apnoea treatment

ZOLL Medical Corporation has announced that it has received approval from the US Food and …

Artivion receives FDA PMA approval of PerClot; transfers designation to Baxter

US cardiac and vascular surgery company Artivion has announced that the US Food and Drug …

Latest content